Wall Street Zen Upgrades Pharvaris (NASDAQ:PHVS) to “Hold”

Pharvaris (NASDAQ:PHVS) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Several other equities research analysts also recently issued reports on the company. Leerink Partners set a $38.00 price target on Pharvaris in a report on Wednesday, December 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a research note on Wednesday, October 8th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price on shares of Pharvaris in a report on Wednesday, December 3rd. Wedbush increased their price target on shares of Pharvaris from $27.00 to $30.00 and gave the company an “outperform” rating in a report on Thursday, November 13th. Finally, Citigroup restated a “market outperform” rating on shares of Pharvaris in a research report on Wednesday, November 19th. Nine investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Pharvaris has a consensus rating of “Moderate Buy” and an average target price of $40.56.

Pharvaris Stock Performance

NASDAQ PHVS opened at $26.48 on Friday. The business has a 50 day simple moving average of $24.81 and a 200 day simple moving average of $22.79. Pharvaris has a 52-week low of $11.51 and a 52-week high of $29.80. The stock has a market cap of $1.38 billion, a price-to-earnings ratio of -8.25 and a beta of -2.79.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.08. On average, analysts predict that Pharvaris will post -2.71 EPS for the current year.

Hedge Funds Weigh In On Pharvaris

Large investors have recently bought and sold shares of the company. Palumbo Wealth Management LLC boosted its position in Pharvaris by 3.2% during the 2nd quarter. Palumbo Wealth Management LLC now owns 14,549 shares of the company’s stock worth $256,000 after buying an additional 447 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after acquiring an additional 783 shares during the last quarter. HighVista Strategies LLC raised its stake in shares of Pharvaris by 4.3% during the second quarter. HighVista Strategies LLC now owns 23,739 shares of the company’s stock valued at $418,000 after acquiring an additional 971 shares during the last quarter. California State Teachers Retirement System lifted its holdings in shares of Pharvaris by 9.8% during the second quarter. California State Teachers Retirement System now owns 14,048 shares of the company’s stock worth $247,000 after purchasing an additional 1,257 shares during the period. Finally, Legal & General Group Plc increased its holdings in Pharvaris by 17.2% in the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock valued at $203,000 after purchasing an additional 1,695 shares during the period.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.